OTTAWA, Nov. 16, 2015 /CNW/ - Annidis
Corporation (TSX Venture: RHA) ("Annidis" or the
"Company") announces that, subject to the final approval of
the TSX Venture Exchange, it has granted incentive stock options to
certain employees and consultants of Annidis for the purchase up to
an aggregate of 350,000 common shares in the capital stock of
Annidis. The options are exercisable at a price of $0.20 per common share and expire on November 16, 2020.
About Annidis Corporation
Annidis (TSX-V: RHA) has developed and is marketing a new
imaging platform technology based on Multi-Spectral Imaging (MSI).
This new technology is opening a new frontier in disease
identification and its management. The Annidis MSI technology
allows eye-care professionals to view non-invasively the deepest
areas of the eye aiding eye care professionals in the early
identification and treatment of debilitating eye diseases. The
Corporation's existing RHA 2020-U Gold, used by eye care
professionals as a broad based tool for detecting early-onset of
eye related diseases such as Dry AMD, has a potential market of
over 20,000 clinics in North
America. The RHA Platinum MD will further strengthen the
value proposition allowing doctors to visualize choroidal and
retinal vasculature non-invasively. The RHA Platinum MD has global
market potential of more than 100,000 Ophthalmologists.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Annidis Corporation